Current management of NSCLC in Asia Pacific
What’s new in the management of non-mutated NSCLC after progression to immunotherapy treatment
Defining optimal sequencing in HCC with evidence and experience-based discussion
How can we further optimize the management of RCC patients
Panel discussion and closing